Biotech Values

[bladerunner1717]

CEO of Novartis' Sandoz:


According to Forbes, Jeff George (CEO of Novartis’ Sandoz) had this to say:


“It underscores that the FDA really does have the institutional courage to approve affordable high quality alternatives to some of the more difficult-to-make products that are out there. There were a lot of interests lined up against this approval.”


Institutional courage, wow, the rhetoric here is fun to watch. Of course, there are billions of dollars at stake, so why expect otherwise?



Bladerunner